Abbreviated Name

Liver Rapid Ref Set App: Yamada (2011)

Lead Investigator

Yamada, Hiro — Wako Diagnostics

Coordinating Investigator

Zheng, Yingye — Fred Hutchinson Cancer Center

Involved Investigators

• Yamada, Hiro — Wako Diagnostics
• Srivastava, Sudhir — National Cancer Institute
• Zheng, Yingye — Fred Hutchinson Cancer Center

Abstract

See objectives

Aims

Effectively measure AFP-L3 and DCP for early detection of HCC.

Analytic Method

Sensitivity and specificity of AFP, AFP-L3% and DCP assays on the uTASWako i30 will be calculated for the patients using several cutoff values (5%, 7%, 10% etc). Sensitivity by tumor characteristics (stage, size and number) will be evaluated. For three single markers, i.e. AFP_wako (AFP from Wako), AFP_L3 and DCP), the data was analyzed by two steps: (1), the Receiver Operating Characteristic (ROC) curve was plotted to show the marker overall performance differences by the areas under the Curve (AUC)and their 95% confidence intervals (CI), they were contrasted with the AFP values from EDRN; and (2) these markers were compared with the standard AFP on the optimal cutoff values and their associated sensitivity and specificity; the underlying optimal estimation was basis on the maximum sum of se. and sp. To know combination potentials among these three single markers from Wako, the logistic regression model was then applied to judge if and how the two markers AFP_L3 and DCP could be combined with the values of AFP_W and the standard AFP. The marker values were transformed by their logarithm functions. These logarithm based marker values were regarded as the independent variables to be put into the logit models by the forward selection. The model based linear scores were then used as the combined marker indicators to do further data analysis for the combined markers in ROC performances.

Outcome

See objectives

Publications

• No publications available at this time for this protocol.

Biomarkers

• AFP
• AFP-L3
• DCP
• DCP and AFP-L3 risk biomarkers for HCC

Data Collections

• No data collections available at this time for this protocol.

Start Date

Feb 28 2011

Estimated Finish Date

Jun 28 2011

Finish Date

May 4 2011

Protocol ID

327

Protocol Type

Reference Set

Fields of Research

• Proteomics

Collaborative Group

G.I. and Other Associated Cancers Research Group

Cancer Types

• Liver cell carcinoma

Phased Status

1